Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ciraparantag
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 20, 2017
Lead Product(s) : Ciraparantag
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciraparantag
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2017
Lead Product(s) : Ciraparantag
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Quintiles Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2014
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Quintiles Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Duke Clinical Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 04, 2014
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Duke Clinical Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciraparantag
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2014
Lead Product(s) : Ciraparantag
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciraparantag
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2014
Lead Product(s) : Ciraparantag
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Profil Institut für Stoffwechselforschung GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
August 01, 2014
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Profil Institut für Stoffwechselforschung GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 14-C PER977
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-label, Single-dose, Non-randomized Study of IV 14C-labeled PER977 in Healthy Male Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
August 01, 2014
Lead Product(s) : 14-C PER977
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2013
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable